Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

43.31
-0.5300-1.21%
Post-market: 43.860.5500+1.27%16:31 EST
Volume:1.27M
Turnover:54.62M
Market Cap:3.71B
PE:-9.98
High:43.74
Open:42.57
Low:41.53
Close:43.84
Loading ...

Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?

Zacks
·
24 Jan

CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?

Zacks
·
23 Jan

Bargain Basement CRISPR Therapeutics Becomes Takeover Target

TIPRANKS
·
23 Jan

RFK disclosures show holdings in Crispr, Dragonfly Therapeutics, STAT reports

TIPRANKS
·
23 Jan

Stock Track | CRISPR Therapeutics Soars 5.03% as Partner Intellia Doses First Patient in Key Gene Editing Study

Stock Track
·
23 Jan

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire
·
22 Jan

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
22 Jan

Stock Market Today: Dow Jones Pops After These Trump Moves; Tesla Named Top Pick, While 3 Stocks Clear Entries (Live Coverage)

Blockhead
·
22 Jan

Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia

Benzinga
·
19 Jan

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks
·
18 Jan

CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

Zacks
·
17 Jan

Cathie Wood’s ARK Invest Boosts CRISPR Therapeutics (NASDAQ:CRSP) Stake

TIPRANKS
·
17 Jan

Cathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics today

TIPRANKS
·
17 Jan

Promising Developments and Strategic Partnerships Drive Crispr Therapeutics’ Growth Potential

TIPRANKS
·
17 Jan

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

TIPRANKS
·
15 Jan